ClinicalTrials.gg
RecruitingNCT05438732CONCERTOUpdated Dec 3, 2024

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

An interventional study of smaller incision, new generation implantable miniature telescope (SING-IMT) in Age-Related Macular Degeneration and Geographic Atrophy, sponsored by VisionCare, Inc.. Recruiting at 10 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
50th of 107
125 · median 98
Started
2022
with 4 others
No phase
11 of 131
4 open now
Primary completion
2025-12
later than 4 of 44 live
Registered
82nd of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 50th largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2022, is one of 11 with no phase, reaches primary completion later than 4 of the 44 other live ones, and was the 82nd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

Read the detailed description

Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with and without refraction, and also when using an external telescope simulator (ETS) to determine if they are likely to benefit from receiving the IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 12 rehabilitation/training visits with a low vision specialist

03

Conditions studied

  • Age-Related Macular Degeneration
  • Geographic Atrophy

Browse trials for

Keywords

  • cataract
  • best-corrected distance visual acuity
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 125 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be at least 65 years of age at the Pre-operative Visit;
  2. Have ETDRS BCDVA 0.9 to 1.6 logMAR (20/160 to 20/800) at the Pre-operative Visit caused by bilateral central scotomas associated with end-stage AMD;
  3. Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit;
  4. Have been monitored by an eye care professional over the 6-month (or longer) period immediately prior to the Pre-operative Visit and have demonstrated no evidence of active choroidal neovascularization (CNV) prior to the Pre-operative Visit as demonstrated by the following:

    1. lack of need of treatment for CNV over the past 6 months, and
    2. lack of active exudative fluid on optical coherence tomography (OCT) over the past 6 months, and
    3. lack of Retinal hemorrhage on exam over a 6-month period or longer
  5. Agree to participate in post-operative visual training

    For the Implanted Eye:

  6. Have evidence of visually significant cataract at the Pre-operative Visit;
  7. Agree to undergo pre-operative training and assessment (1 or more sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment

    For the Non-Implanted Eye:

  8. Have adequate peripheral vision at the Pre-operative Visit to allow navigation

Exclusion criteria

Exclusion Criteria:

  1. Have cognitive impairment that would interfere with the ability to understand and provide or prevent proper visual training/rehabilitation with the device;
  2. Have any of the following conditions at the Pre-operative Visit:

    1. Stargardt macular dystrophy;
    2. Diabetic retinopathy;
    3. Untreated retinal tears;
    4. Retinal vascular disease;
    5. Optic nerve disease;
    6. History of retinal detachment;
    7. Intraocular tumor;
    8. Retinitis pigmentosa;
  3. History of -induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit;
  4. Have known allergy to post-operative medications;
  5. History of eye rubbing or an ocular condition that predisposes subject to eye rubbing;
  6. Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit;
  7. Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety;
  8. Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study;
  9. Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit

    For the Implanted Eye:

  10. Have central anterior chamber depth (ACD) \<3.0 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit;
  11. Have an Endothelial Cell Density (ECD) below:

    1. 2,000 cells per millimeter, if 65-84 years old;
    2. 1,800 cells per millimeter, if 85 years old or greater (based on the lowest value of the three cell counts performed by technician at investigative site at the Pre-operative Visit)
  12. Have a history of corneal stromal or endothelial dystrophies, including guttata;
  13. Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit;
  14. Have an Axial Length (AL) \< 21 mm at the Pre-operative Visit;
  15. Have a narrow angle defined as \< grade 2 on the Schaffer scale at the Pre-operative Visit;
  16. Ongoing Inflammatory ocular disease at the Pre-operative Visit;
  17. Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit;
  18. Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery;
  19. Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes;

    For the Non-Implanted Eye:

  20. Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    SING-IMT Implanted

    the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision

    Device: smaller incision, new generation implantable miniature telescope (SING-IMT)

Interventions

  • Devicesmaller incision, new generation implantable miniature telescope (SING-IMT)

    The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)

07

What researchers measure

Primary outcomes

  1. Primary Effectiveness Outcome

    Proportion of study eyes with an improvement of 10 or more ETDRS letters (0.2 logMAR) in either BCDVA or BCNVA at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

    Time frame: Approximately 12-months post-operatively (330-420 days)

  2. Primary Safety Outcome

    Percent change in endothelial cell density (ECD) from Pre-operative Visit in study eyes at Visit 5 (330 to 420 days post-operatively)

    Time frame: Approximately 12-months post-operatively (330-420 days)

Secondary outcomes

  1. Best-corrected distance visual acuity (BCDVA)

    Post-operative BCDVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

    Time frame: Approximately 12-months post-operatively (330-420 days)

  2. Best-corrected near visual acuity (BCNVA)

    Post-operative BCNVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit

    Time frame: Approximately 12-months post-operatively (330-420 days)

  3. Anterior Chamber Depth

    Anterior Chamber Depth in study eyes, defined as the distance between the corneal endothelium and the front surface of the IMT, at Visit 5 (330 to 420 days post-operatively)

    Time frame: Approximately 12-months post-operatively (330-420 days)

  4. IMT position

    IMT tilt and centration in study eyes at Visit 5 (330 to 420 days post-operatively)

    Time frame: Approximately 12-months post-operatively (330-420 days)

  5. Adverse Events

    Rates of adverse events from Operative Visit through Visit 5 (330 to 420 days post-operatively)

    Time frame: Approximately 12-months post-operatively (330-420 days)

  6. Posterior Capsule Opacification

    Rates of posterior capsule opacification in study eyes at post-operative visit 5 (330 to 420 days post-operatively)

    Time frame: Approximately 12-months post-operatively (330-420 days)

08

Study locations

10 of 10 sites recruiting
  • Loma Linda University
    Loma Linda, California 92354, United States
    Recruiting
    • Rebecca Pereyra, Study Coordinator · Contactrpereyra@llu.edu · +1 (909) 558--2168
    • Norlisha Borntrager, Study Director · ContactNBorntrager@llu.edu · +1 (909) 558-2233
    • Michael Rauser, MD · Contact
  • Eye Physicians of Long Beach
    Long Beach, California 90815, United States
    Recruiting
    • Lisa Bejarano, Study Coordinator · Contactlisab@eplb.com · +1 (562) 799-2020
    • Carlos Martinez, MD · Contact
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
    Recruiting
    • Peggy Jelemensky, Study Coordinator · ContactSRQresearch@aol.com · +1 (941) 921-5335
    • Marc Levy, MD · Contact
  • Tallman Eye Associates
    Lawrence, Massachusetts 01841, United States
    Recruiting
    • Flor Flores, Study Coordinator · ContactResearch@tallmaneye.com · +1 (617) 470-5080
    • Justine St. Croix, VP of Operations · Contact+1 (978) 688-6182
    • Tomasz Stryjewski, MD · Contact
  • Oakland Ophthalmic Surgery
    Birmingham, Michigan 48009, United States
    Recruiting
  • Vance Thompson Vision
    Omaha, Nebraska 68137, United States
    Recruiting
  • Atlantic Eye Physicians
    Eatontown, New Jersey 07724, United States
    Recruiting
    • Joseph Valeri, Study Coordinator · Contactjdvaleri@gmail.com · +1 (201) 705-7139
    • Ravi Patel, MD · Contact
  • Western Carolina Retinal Associates
    Asheville, North Carolina 28803, United States
    Recruiting
    • Amy Moore, Study Coordinator · Contactamoore@aea1961.com · +1 (828) 258-1586
    • Lea Raymer, Director of Research · Contactldoll@aea1961.com
    • W. Zachery Bridges, Jr., MD · Contact
  • Cleveland Clinic | Cole Eye Institute
    Cleveland, Ohio 44195, United States
    Recruiting
    • Jessica Wolfe, OD, MS, Research Coordinator · Contactwolfej11@ccf.org · +1 (216) 445-5248
    • Aleksandra Rachitskaya, MD · Contact
  • Methodist Eye Associates | Houston Methodist
    Houston, Texas 77030, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2025, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Jun 30, 2022
StartActual
Jun 16, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05438732
Lead sponsor
VisionCare, Inc.
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Jun 16, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 3, 2024

Study contacts

Rebecca Kammer, OD, PhD
Contact
rkammer@samsaravision.com
+1 (714) 728-1575
Colleen Collier
Contact
ccollier@samsaravision.com
+1 (609) 213-9420
Rebecca J Kammer, OD, PhD
study director · Samsara Vision Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion